Background {#Sec1}
==========

Esophageal cancer is the eighth most common cancer type and sixth leading cause of cancer death worldwide, which was responsible for 482,300 new cases and 406,800 deaths in 2008 \[[@CR1]\]. In some high-risk regions such as North of China, esophageal cancer represents a major health problem, which is the fourth leading cause of cancer death. Squamous cell carcinoma is the major pathological type and accounts for more than 90% of esophageal cancer cases in Chinese patients \[[@CR2]\]. Despite the advancement in diagnosis and treatment modalities, esophageal squamous cell carcinoma (ESCC) still shows a dismal prognosis with a 5-year survival rate less than 15% \[[@CR3],[@CR4]\]. It is important to identify effective biomarkers to recognize unique biological characteristics of ESCC patients, in order to guide more individualized treatment.

It has been demonstrated that the alteration of coagulation pathways was associated with tumor progression and poor prognosis in various malignancies \[[@CR5],[@CR6]\]. More than half of patients with metastatic disease have some abnormalities in hemostatic parameters \[[@CR7]\]. Fibrinogen is a dimeric glycoprotein synthesized by hepatocytes, which plays a key role in clot formation and wound healing. It binds to platelets to support platelet aggregation after being converted to fibrin. Elevated plasma fibrinogen levels reflect a thrombophilic state that arises from the capacity of tumor cells to release coagulant molecules \[[@CR8]\]. Fibrinogen is also a pro-inflammatory protein, which usually acts as an acute-phase protein in response to wound healing, infection, and inflammation \[[@CR9]\]. Recently, the plasma fibrinogen level was found to correlate with clinicopathological factors and prognosis in gastric cancer, colon cancer, endometrial cancer, and so on \[[@CR5],[@CR10],[@CR11]\]. Platelet is another crucial player of the coagulation system. Platelet could facilitate metastasis through promoting disseminated tumor cell survival in the circulation system, and extravasation and angiogenesis in the microenvironment of target sites \[[@CR12]\]. Several studies have demonstrated that an elevated platelet count correlate with poor prognosis in several types of solid cancer, including lung cancer, colorectal cancer, gastric cancer, and so on \[[@CR13]-[@CR15]\]. However, the exact role of plasma fibrinogen level and platelet count in ESCC remains inconclusive.

In the present study, we examined the clinical significance of preoperative plasma fibrinogen level and platelet count in ESCC treated by curative surgery.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

A total of 119 patients who underwent potential radical surgery for ESCC in Qilu Hospital of Shandong University between 1 January and 30 September 2008 were included in the study. Patients were already excluded because of palliative surgery, neoadjuvant treatment, perioperative mortality, distant metastasis, stage 0 disease, and lost to follow-up. The protocol of the study was approved by the Institutional Ethics Committee of the Qilu Hospital of Shandong University. All the patient demographic and clinical data including age, gender, histological grade, lymph node status, pTNM stage, and adjuvant treatment were abstracted from the clinical records. The stage of disease was determined according to the TNM system of the International Union Against Cancer (6th edition). A thorough histological examination was made using H&E-stained tissue preparations and the histological grade was determined according to the degree of differentiation of the tumor.

Fibrinogen and platelet measurement {#Sec4}
-----------------------------------

As a part of clinical routine, the pretreatment plasma fibrinogen levels and platelet counts were measured from early morning samples and were collected 24 h to 1 week before surgery after overnight fasting. Plasma fibrinogen levels and platelet counts greater than 4.0 g/L and 300 × 10^9^/L were defined as hyperfibrinogenemia and thrombocytosis, respectively, according to the normal reference range in our hospital.

Follow up {#Sec5}
---------

Follow-up visit was performed every 3 months for the first 2 years and every 6 months for the next up to death or the end of the study. Data was censored at the last follow-up for patients without recurrence or death. At each visit, a clinical history was taken and a physical examination was performed. Routing diagnostic imaging methods included barium meal fluoroscopy and computer tomography. Disease-free survival (DFS) was defined from the date of the definitive surgery to the date of local or distant recurrence, mortality by any cause, or the last follow-up. Overall survival (OS) was calculated as the time from the date of surgery to that of mortality or censoring.

Statistical analysis {#Sec6}
--------------------

Pretreatment plasma fibrinogen levels and platelet counts were reported as the mean ± SD. Continuous variables in different subgroups were compared using an unpaired *t*-test and one-way analysis of variance. Categorical variables were compared using chi-square test. Bivariate correlation analysis was performed using Pearson's correlation coefficient analysis. Kaplan-Meier curves were used to estimate the distribution of DFS and OS, and log-rank test was performed to compare the difference between the survival curves. Variables, which were identified as statistically significant in univariate analysis, were included in the multivariate survival analysis using the Cox proportional hazard model. All statistical analyses were performed using SPSS 13.0 statistical software (SPSS Inc, Chicago, IL, USA). *P* values \<0.05 were considered of statistical significance.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

Median age was 60 years (range, 42 to 78 years), and 80% of patients were male. Tumor locations were upper thoracic in 15 patients, mid-thoracic in 67 patients, and lower thoracic in 37 patients. The mean length of the tumor was 3.85 cm (range, 0.5 to 8.5). The histopathological differentiations were poor in 35 cases, moderate in 51 cases, and well in 33 cases. 75 patients (63%) had T3/T4 tumors. Forty-four patients (27%) have positive lymph nodes. The pathological stages were stage I in 21 patients, stage II in 58 patients and stage III in 40 patients. 71 patients (59.7%) received surgery alone, 11 (9.2%) received postoperative chemotherapy, 25 (21%) received postoperative radiotherapy, and 12 (10.1%) received postoperative chemoradiation. Eighty-one patients (68.1%) had recurrence, and 74 (62.2%) died during the follow-up. The estimated 1-, 3-, and 5-year DFS and OS rates were 75%, 49%, and 37% and 87%, 55%, and 41%, respectively. Median DFS was 33.8 months (range, 1.5 to 71.5 months). Median OS was 45.8 months (range, 2.6 to 71.5 months).

Correlation between plasma fibrinogen, platelet count, and clinicopathological parameters {#Sec9}
-----------------------------------------------------------------------------------------

The plasma fibrinogen levels in preoperative esophageal cancer patients ranged from 2.2 to 6.91 g/L (mean ± SD 3.85 ± 0.95 g/L). The incidence of hyperfibrinogenemia was 43.7% (52/119, cut-off value 4.0 g/L). Hyperfibrinogenemia was found to be positively correlated with a larger tumor size (*P* = 0.027), increased depth of invasion (*P* = 0.013), advanced pathological stages (*P* = 0.011), and disease recurrence (*P* = 0.026). No significant correlation was identified between fibrinogen levels and tumor location or lymph node metastasis (Table [1](#Tab1){ref-type="table"}).Table 1**Relationship of preoperative plasma fibrinogen level with clinicopathological parameterVariable*N*Fibrinogen level*P*** **valueFibrinogen level*P*** **valueMean ± SDNormalHyperfibrinogenemia(g/L)(1.5 to 4 g/L)(≥4 g/L)**Gender  Male953.94 ± 0.98*0.034*51440.252  Female243.48 ± 0.73168Age  \<60593.7 ± 0.940.10138210.077  ≥60603.99 ± 0.952931Smoking history  Yes713.91 ± 0.950.37129190.457  No483.75 ± 0.963833Location  Upper153.56 ± 0.740.144960.528  Middle673.78 ± 0.994027  Lower374.08 ± 0.931819Tumor length  \<3.85 cm643.56 ± 0.88*\<0.001*4222*0.027*  ≥3.85 cm554.18 ± 0.932530Differentiation  Well333.94 ± 0.810.78217160.676  Moderate513.81 ± 1.093120  Poor353.8 ± 0.871916Tumor stage  T1183.25 ± 0.68*0.001*153*0.013*  T2263.67 ± 0.91179  T3673.97 ± 0.923334  T484.69 ± 1.1126Lymph node status  Negative753.77 ± 0.940.26746290.149  Positive443.97 ± 0.972123Pathological stages  I213.48 ± 0.81*0.034*156*0.011*  II583.79 ± 0.983721  III404.12 ± 0.911525Adjuvant treatment  None713.87 ± 0.950.96237340.307  Radiotherapy253.83 ± 0.971312  Chemotherapy113.9 ± 0.8283  CRT123.72 ± 1.1193Recurrence  Yes813.94 ± 0.970.1164041*0.026*  No383.65 ± 0.892711SD, standard deviation; CRT, chemoradiotherapy. *P* \< 0.05 is of significance.

The platelet counts ranged from 78 × 10^9^/L to 936 × 10^9^/L (mean ± SD 254.51 ± 89.26 × 10^9^/L). The incidence of thrombocytosis was 20.2% (24/119, cut-off value 300 × 10^9^/L). Thrombocytosis was more frequently seen in male gender (*P* = 0.029) and non-smokers (*P* = 0.008). There was no significant correlation between the platelet count and the larger tumor size, increased depth of invasion, advanced pathological stages, or disease recurrence (Table [2](#Tab2){ref-type="table"}). A significant correlation between plasma fibrinogen levels and platelet counts was observed (*r* = 0.018, *P* = 0.048).Table 2**Relationship of preoperative platelet count with clinicopathological parametersVariable*N*Platelet count*P*** **valuePlatelet count*P*** **valueMean ± SDNormalThrombocytosis(×109/L)\<300 × 109/L≥300 × 109/L**Gender  Male95260.79 ± 96.130.1277223*0.029*  Female24229.67 ± 47.93231Age  \<6059254.86 ± 68.780.96646130.615  ≥6060254.17 ± 106.224911Smoking history  Yes71267.39 ± 105.40.055444*0.008*  No48235.46 ± 53.235120Location  Upper15260.93 ± 82.510.6961230.964  Middle67248.36 ± 59.935413  Lower37263.05 ± 129.3298Tumor length  \<3.85 cm64250.18 ± 103.940.57154100.183  ≥3.85 cm55259.54 ± 68.964114Differentiation  Well33263.39 ± 136.030.7932670.568  Moderate51250.04 ± 69.683912  Poor35252.66 ± 54.62305Tumor stage  T118207.56 ± 51.84*0.034*1710.251  T226247.58 ± 53.27215  T367263.66 ± 105.275215  T48306.13 ± 58.7353Lymph node status  Negative75250.89 ± 99.450.56662130.314  Positive44260.68 ± 69.143311Pathological stages  I21258.19 ± 168.650.2331740.636  II58246.48 ± 54.64810  III40264.23 ± 70.433010Adjuvant treatment  None71259.69 ± 105.060.82356150.788  Radiotherapy25253.48 ± 65.68205  Chemotherapy11235.55 ± 43.03101  CRT12243.42 ± 58.8293Recurrence  Yes251.44 ± 58.060.67566150.513  No261.05 ± 134.37299SD, standard deviation; CRT, chemoradiotherapy. *P* \< 0.05 is of significance.

Survival analysis {#Sec10}
-----------------

We assessed the prognostic values of the preoperative plasma fibrinogen level and platelet count in the ESCC patients included in our study, as shown in Table [3](#Tab3){ref-type="table"}. Patients with hyperfibrinogenemia had lower 5-year disease-free survival (27% *vs*. 45%) and overall survival rates (29% *vs.* 51%) than those with normal plasma fibrinogen concentration. In univariate analysis, hyperfibrinogenemia was associated with poor disease-free (*P* = 0.009, hazard ratio (HR) = 1.784, 95% confidence interval (CI) = 1.153 to 2.761) and overall (*P* = 0.003, HR = 1.992, 95% CI = 1.259 to 3.152) survivals (Figure [1](#Fig1){ref-type="fig"}). Thrombocytosis was not correlated with disease survivals. Clinicopathological factors, which significantly associated with poor disease-free and overall survivals, were advanced T stages, lymph node metastasis, and advanced pTNM stages. In multivariate analysis, only pTNM stages were an independent predictor for disease-free survival (*P* \< 0.001, HR = 2.985, 95% CI = 1.898 to 4.695), and both depth of invasion (*P* = 0.025, HR = 1.895, 95% CI = 1.084 to 3.313) and pTNM stages (*P* \< 0.001, HR = 2.501, 95% CI = 1.52 to 4.114) were independent prognostic factors for overall survival.Table 3**Univariate analysis of survival of esophageal squamous cell carcinoma treated by curative surgeryVariableDisease-free survival*P*** **valueOverall survival*P*** **valueHR (95% CI)HR (95% CI)**Gender (Female)0.939(0.535 to 1.647)0.8260.937(0.523 to 1.677)0.826Age (≥60)0.982(0.634 to 1.519)0.9331.09(0.69 to 1.721)0.712Smoking history1.093(0.697 to 1.717)0.6981.139(0.712 to 1.825)0.587Location  UpperRef.0.432Ref.0.652  Middle0.656(0.346 to 1.246)01980.721(0.36 to 1.442)0.355  Lower0.694(0.349 to 1.378)0.2960.771(0.368 to 1.614)0.49Tumor length (≥3.85 cm)1.178(0.761 to 1.824)0.4621.335(0.846 to 2.106)0.215Differentiation  WellRef.0.2Ref.0.141  Moderate1.595(0.915 to 2.781)0.11.69(0.931 to 3.067)0.084  Poor1.616(0.889 to 2.939)0.1161.819(0.965 to 3.427)0.064Tumor stage  T1Ref.*0.011*Ref.*0.001*  T21.388(0.612 to 3.149)0.4321.591(0.605 to 4.188)0.347  T32.295(1.117 to 4.713)*0.024*3.19(1.36 to 7.481)*0.008*  T44.112(1.568 to 10.786)*0.004*5.968(2.058 to 17.301)*0.001*Lymph node metastasis2.406(1.544 to 3.749)*\<0.001*2.414(1.522 to 3.829)*\<0.001*Pathological stages  IRef.*\<0.001*Ref.*\<0.001*  II1.97(0.944 to 4.113)0.0712.561(1.069 to 6.133)0.035  III4.96(2.35 to 10.471)*\<0.001*6.412(2.669 to 15.404)*\<0.001*Adjuvant treatment  NoneRef.0.133Ref.0.073  Radiotherapy1.672(0.984 to 2.839)0.0571.814(1.058 to 3.111)*0.03*  Chemotherapy0.732(0.312 to 1.714)0.4720.652(0.258 to 1.65)0.367  CRT1.549(0.756 to 3.174)0.2321.521(0.712 to 3.249)0.279Fibrinogen level (≥4 g/L)1.784(1.153 to 2.761)*0.009*1.992(1.259 to 3.152)*0.003*Platelet count (≥300 × 10^9^ /L)0.918(0.524 to 1.608)0.7651.072(0.618 to 1.891)0.809HR, hazard ratio; CI, confidence interval; CRT, chemoradiotherapy. *P* \< 0.05 is of significance.Figure 1Kaplan-Meier analysis of preoperative plasma fibrinogen level in 119 patients with esophageal squamous cell carcinoma. Hyperfibrinogenemia were significantly associated with decreased disease-free survival **(A)** and overall survival **(B)**.

Discussion {#Sec11}
==========

Recently, much attention has been paid to the relationship between hyperfibrinogenemia/thrombocytosis and malignant diseases. Elevated plasma fibrinogen levels and platelet counts have been found in some malignancies, such as gastric cancer, colorectal cancer, lung cancer, and so on \[[@CR11],[@CR16]-[@CR18]\]. In the present study, we analyzed the clinical significance of preoperative plasma fibrinogen level and platelet count in 119 patients with ESCC received curative surgery. We found that the incidence of hyperfibrinogenemia and thrombocytosis were 43.7% (52/119, cut-off value 4.0 g/L) and 20.2% (24/119, cut-off value 300 × 109/L), respectively, in the resectable ESCC patients. Hyperfibrinogenemia was found to be positively correlated with the increased tumor length, increased depth of invasion, and advanced pathological stages. Hyperfibrinogenemia was associated with poor disease-free and overall survivals in univariate analysis, but not an independent predictor for prognosis in multivariate analysis. Thrombocytosis was not associated with clinical outcome and clinicopathological parameters such as depth of invasion, lymph node metastasis, or pathological stages. We also observe a significant correlation plasma fibrinogen levels and platelet counts (*r* = 0.018, *P* = 0.048).

To our best knowledge, only two studies analyzed the clinical significance of plasma fibrinogen in ESCC. Takeuchi *et al*. \[[@CR19]\] showed that pretreatment plasma fibrinogen correlates with tumor progression and metastasis in patients with ESCC. However, they did not show any association of pretreatment plasma fibrinogen with survivals in patients treated by surgery. Matsuda and colleagues \[[@CR20]\] found that plasma fibrinogen level as a predictive marker for postoperative recurrence of ESCC in patients receiving neoadjuvant treatment. In the study, we firstly analyzed the clinical significance of pretreatment plasma fibrinogen in 119 ESCC treated by curative surgery without neoadjuvant treatment. Our study showed that hyperfibrinogenemia was significantly associated with advanced disease.

For thrombocytosis, the role of its prognostic significance is also inconclusive. Feng *et al*. \[[@CR21]\] analyzed the clinical significance of preoperative thrombocytosis in a group of patients with ESCC and found that preoperative platelet count is a predictive factor for long-term survival in ESCC, especially in node-positive patients. Shimada *et al*. \[[@CR22]\] found that a high platelet count is associated with tumor progression and poor survival in patients with esophageal cancer. However, the present study did not show that thrombocytosis was associated with clinical outcome and any pathological parameters in ESCC treat by curative surgery. The reason for the inconsistent results may be that our study included patients with relative early stage compared with previous studies.

The exact mechanism linking coagulation pathways and cancer progression remains unclear. Fibrinogen is a dimeric molecule with multiple integrin and non-integrin binding motifs, and cancer cells often express high levels of integrins or intercellular adhesion molecule 1. Fibrinogen deposition around tumor cells enhances the interaction between these cells and platelets, which effectively form microemboli in target organs \[[@CR23]\]. Fibrinogen may also bind to growth factors, such as fibroblast growth factors and vascular endothelial cell growth factors, and thereby regulate endothelial cell proliferation and angiogenesis \[[@CR24]\]. Fibrinogen layers help tumor cells block natural killer cytotoxicity with thrombin, which can protect tumor cells from the innate immune system \[[@CR25]\].

Platelets, which were produced by mature bone marrow megakaryocytes, play an important role in arresting hemorrhage after tissue trauma or vascular injury. Platelets take an active part in the initiation and development of the inflammatory process by adhering to the cells of the vascular walls and by releasing of chemokines, cytokines, proteases, and procoagulants \[[@CR26]\]. Platelets release various cytokines, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), during blood clotting. The VEGF and PDGF family of proteins have a significant role in regulating tumor cell growth and angiogenesis \[[@CR27]\]. Moreover, platelets expressing immunoregulatory protein such as glucocorticoid-induced TNF-related protein may protect the cancer cells from the host's immune system \[[@CR28]\].

The potential limitations of the present study include the use of a retrospective design. In order to select patients with a more uniform background, we only included esophageal cancer patients treated by potential curative surgery and excluded those received neoadjuvant treatment, which may also limit the general application of the results. Furthermore, larger prospective studies will be needed to confirm these preliminary results.

Conclusions {#Sec12}
===========

Our study demonstrated that hyperfibrinogenemia is a valuable predictor for disease progression in ESCC. Anticoagulation therapy might be considered to control cancer progression in future studies. Additionally, the introduction of the convenient prognostic factors such as plasma fibrinogen can assist clinicians with better individualization of their therapeutic approach based on the risk stratification.
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